CRISPR Therapeutics AG ist eine Aktie aus dem Premium-Bereich von aktien.guide. Bitte anmelden, um einen Alarm für CRISPR Therapeutics AG zu aktivieren.
Kostenlos registrieren
Bitte registriere Dich kostenlos, um CRISPR Therapeutics AG zu Deinem Portfolio hinzuzufügen.
While a weakening economy and a subsequent dip in the stock market are unfortunate, they are inevitabilities. Even booming segments like the biotech sector are not immune to the general trend of recessions that Western economies experienced over the last 40 years or so.
CRISPR/Cas9 technology allows for precise editing of DNA, potentially treating human diseases by replacing entire genes. CRISPR Therapeutics has developed the first FDA-approved ex vivo CRISPR/Cas9 therapy, Casgevy, for sickle cell disease and transfusion-dependent beta-thalassemia. The market seems pessimistic about the commercialization of these therapies, but if successful, CRISPR Therapeuti...
Despite recent FDA approvals for its groundbreaking gene editing technology, CRISPR Therapeutics' stock has experienced a decline in value. The company's pipeline of treatments for various diseases presents a significant opportunity for future growth and market expansion. CRISPR Therapeutics has managed financial risks through partnerships and has enough cash on hand to fund operations for at l...
ZUG, Switzerland and BOSTON, April 22, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced an oral presentation highlighting the Company's lipid nanoparticle (LNP) approach for ocular editing will be presented at the American Society of Gene & Cell Therapy (ASGCT) 2...
CRISPR Therapeutics AG (NASDAQ:CRSP ) Annual Needham Virtual Healthcare Conference Call April 10, 2024 11:45 AM ET Company Participants Samarth Kulkarni - Chief Executive Officer and Chairman Conference Call Participants Gil Blum - Needham & Company Gil Blum Good morning, everyone, and thank you for joining us on the Third Day of the Needham Healthcare Conference. My name is Gil Blum and I am a...
aktien.guide ist das Tool zum einfachen Finden, Analysieren und Beobachten von Aktien. Lerne von erfolgreichen Investoren und triff fundierte Anlageentscheidungen. Wir machen Dich zum selbstbestimmten Investor.